Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors

Clinical Radiology

Volumn 72, Issue 7, 2017, Pages 521-533

  Alessandrino, F ^a,b   Tirumani, S H ^b   Krajewski, K M ^a,b   Shinagare, A B ^a,b   Jagannathan, J P ^a,b   Ramaiya, N H ^a,b   Di Salvo, D N ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNE CHECKPOINT INHIBITOR; IMMUNOMODULATING AGENT; MOLECULAR THERAPY AGENT; UNCLASSIFIED DRUG; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB;

CANCER CENTER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CHRONIC LIVER DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOGRAPHY; HUMAN; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MOLECULARLY TARGETED THERAPY; NONALCOHOLIC FATTY LIVER; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; REVIEW; STEATOSIS; SYSTEMIC THERAPY; TERTIARY CARE CENTER; TOXIC HEPATITIS; ADVERSE EFFECTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; DECISION TREE; DIAGNOSTIC IMAGING;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CANCER CARE FACILITIES; CHEMICAL AND DRUG INDUCED LIVER INJURY; DECISION TREES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MOLECULAR TARGETED THERAPY; TERTIARY CARE CENTERS;

EID: 85018960602     PISSN: 00099260     EISSN: 1365229X     Source Type: Journal    
DOI: 10.1016/j.crad.2017.04.003     Document Type: Review

References (100)

1. Howard, S.A., Krajewski, K.M., Jagannathan, J.P., et al. A new look at toxicity in the era of precision oncology: imaging findings, their relationship with tumour response, and effect on metastasectomy. AJR Am J Roentgenol 207:1 (2016), 4–14.
2. Tirumani, S.H., Kim, K.W., Nishino, M., et al. Update on the role of imaging in management of metastatic colorectal cancer. RadioGraphics 34:7 (2014), 1908–1928.
3. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J Clin 66:1 (2016), 7–30.
4. White, M.A., Fong, Y., Singh, G., Chemotherapy-associated hepatotoxicities. Surg Clin North Am 96:2 (2016), 207–217.
5. Ngo, D., Jia, J.B., Green, C.S., et al. Cancer therapy related complications in the liver, pancreas, and biliary system: an imaging perspective. Insights Imaging 6:6 (2015), 665–677.
6. Colsky, J., Greenspan, E.M., Warren, T.N., Hepatic fibrosis in children with acute leukemia after therapy with folic acid antagonists. AMA Arch Pathol 59:2 (1955), 198–206.
7. Howard, S.A.H., Krajewski, K.M., Thornton, E., et al. Decade of molecular targeted therapy: abdominal manifestations of drug toxicities — what radiologists should know. AJR Am J Roentgenol 199:1 (2012), 58–64.
8. Cohen, M.H., Williams, G., Johnson, J.R., et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:5 (2002), 935–942.
9. Boutros, C., Tarhini, A., Routier, E., et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13:8 (2016), 473–486.
10. Michot, J.M., Bigenwald, C., Champiat, S., et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54 (2016), 139–148.
11. Maor, Y., Malnick, S., Liver injury induced by anti-cancer chemotherapy and radiation therapy. Int J Hepatol, 2013, 2013, 815105.
12. Navarro, V.J., Senior, J.R., Drug-related hepatotoxicity. N Engl J Med 354:7 (2006), 731–739.
13. Stine, J.G., Chalasani, N., Chronic liver injury induced by drugs: a systematic review. Liver Int 35:11 (2015), 2343–2353.
14. Lee, W.M., Drug-induced hepatotoxicity. N Engl J Med 349:5 (2003), 474–485.
15. Guengerich, F.P., Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14 (2001), 611–650.
16. Aithal, G.P., Watkins, P.B., Andrade, R.J., et al. Case definition and phenotype standardization in DILI. Clin Pharmacol Ther 89:6 (2011), 806–815.
17. Keraliya, A.R., Rosenthal, M.H., Krajewski, K.M., et al. Imaging of fluid in cancer patients treated with systemic therapy: chemotherapy, molecular targeted therapy, and haematopoietic stem cell transplantation. AJR Am J Rogentgenol 205:4 (2015), 709–719.
18. Han, N.Y., Park, B.J., Kim, M.J., Hepatic parenchymal heterogeneity on contrast-enhanced CT scans following oxaliplatin-based chemotherapy: natural history and association with clinical evidence of sinusoidal obstruction syndrome. Radiology 276:3 (2015), 766–774.
19. Shinagare, A.B., Jagannathan, J.P., Krajewski, K.M., et al. Liver metastases in the era of molecular targeted therapy: new faces of treatment response. AJR Am J Rogentgenol 201:1 (2013), W15–W28.
20. King, P.D., Perry, M.C., Hepatotoxicity of chemotherapy. Oncologist 6:2 (2001), 162–176.
21. McGettigan, M.J., Menias, C.O., Gao, Z.J., et al. Imaging of drug-induced complications in the gastrointestinal system. RadioGraphics 36:1 (2016), 71–87.
22. Park, S.J., Kim, J.D., Seo, Y.S., et al. Computed tomography findings for predicting severe acute hepatitis with prolonged cholestasis. World J Gastroenterol 19:16 (2013), 2543–2549.
23. Boll, D.T., Merkle, E.M., Diffuse liver disease: strategies for hepatic CT and MR imaging. RadioGraphics 29:6 (2009), 1591–1614.
24. Cooley, C., Nishino, M., Jagannathan, J., et al. Clinical problem solving: utility of sonography in oncologic patients. J Ultrasound Med 33:1 (2014), 9–22.
25. Loriot, Y., Perlemuter, G., Malka, D., et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol 5:5 (2008), 268–278.
26. Peroukides, S., Makatsoris, T., Koutras, A., et al. Lapatinib-induced hepatitis: a case report. World J Gastroenterol 17:18 (2011), 2349–2352.
27. Kim, K.W., Ramaiya, N.H., Krajewski, K.M., et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 31:4 (2013), 1071–1077.
28. Iacovelli, R., Palazzo, A., Procopio, G., et al. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol 77:6 (2014), 929–938.
29. Powles, T., Bracarda, S., Chen, M., et al. Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients. Eur J Cancer 51:10 (2015), 1293–1302.
30. Bunchorntavakul, C., Reddy, K.R., Drug hepatotoxicity: newer agents. Clin Liver Dis 21:1 (2017), 115–134.
31. Shepherd, F.A., Rodrigues Pereira, J., Ciuleanu, T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:2 (2005 Jul 14), 123–132.
32. Maemondo, M., Inoue, A., Kobayashi, K., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:25 (2010), 2380–2388.
33. Sogaard, K.K., Astrup, L.B., Vilstrup, H., et al. Portal vein thrombosis; risk factors, clinical presentation and treatment. BMC Gastroenterol, 7, 2007, 34.
34. Inno, A., Basso, M., Vecchio, F.M., et al. Anastrozole-related acute hepatitis with autoimmune features: a case report. BMC Gastroenterol, 11, 2011, 32.
35. Mahale, P., Kontoyiannis, D.P., Chemaly, R.F., et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol 57:6 (2012), 1177–1185.
36. Itai, Y., Sekiyama, K., Ahmadi, T., et al. Fulminant hepatic failure: observation with serial CT. Radiology 202:2 (1997), 379–382.
37. Abu-Judeh, H.H., The “starry sky” liver with right-sided heart failure. AJR Am J Rogentgenol, 178, 2002, 78.
38. Romero, M., Palmer, S.L., Kahn, J.A., et al. Imaging appearance in acute liver failure: correlation with clinical and pathology findings. Dig Dis Sci 59:8 (2014), 1987–1995.
39. Weber, J.S., Kähler, K.C., Hauschild, A., Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:21 (2012), 2691–2697.
40. Kwak, J.J., Tirumani, S.H., Van den Abbeele, A.D., et al. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. RadioGraphics 35:2 (2015), 424–437.
41. Tirumani, S.H., Ramaiya, N.H., Keraliya, A., et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 3:10 (2015), 1185–1192.
42. Hofmann, L., Forschner, A., Loquai, C., et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60 (2016), 190–209.
43. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1 (2015), 23–34.
44. Cleary, J.M., Tanabe, K.T., Lauwers, G.Y., et al. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist 14:11 (2009), 1095–1105.
45. Fong, Y., Bentrem, D.J., CASH (chemotherapy-associated steatohepatitis) costs. Ann Surg 243:1 (2006), 8–9.
46. Riippa, P., Kauppila, A., Sundströ, et al. Hepatic impairment during simultaneous administration of medroxyprogesterone acetate and tamoxifen in the treatment of endometrial and ovarian carcinoma. Anti-cancer Res 4 (1984), 109–112.
47. Ushijima, K., Yahata, H., Yoshikawa, H., et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25 (2007), 2798–2803.
48. Coskun, U., Töruner, F.B., Günel, N., Tamoxifen therapy and hepatic steatosis. Neoplasma 49 (2002), 61–64.
49. Nishino, M., Hayakawa, K., Nakamura, Y., et al. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am J Rogentgenol 180 (2003), 129–134.
50. Michaels, A.Y., Keraliya, A.R., Tirumani, S.H., et al. Systemic treatment in breast cancer: a primer for radiologists. Insights Imaging 7:1 (2016), 131–144.
51. Wilkins, T., Tadkod, A., Hepburn, I., et al. Nonalcoholic fatty liver disease: diagnosis and management. Am Fam Physician 88:1 (2013), 35–42.
52. Lall, C.G., Aisen, A.M., Bansal, N., et al. Nonalcoholic fatty liver disease. AJR Am J Rogentgenol 190:4 (2008), 993–1002.
53. Saadeh, S., Younossi, Z.M., Remer, E.M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123 (2002), 745–750.
54. Dyson, J.K., McPherson, S., Anstee, Q.M., Non-alcoholic fatty liver disease: noninvasive investigation and risk stratification. J Clin Pathol 66:12 (2013), 1033–1045.
55. Qayyum, A., Nystrom, M., Noworolski, S.M., et al. MRI steatosis grading: development and initial validation of a color mapping system. AJR Am J Rogentgenol 198:3 (2012), 582–588.
56. Boyce, C.J., Pickhardt, P.J., Kim, D.H., et al. Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. AJR Am J Rogentgenol 194:3 (2010), 623–638.
57. Tchelepi, H., Ralls, P.W., Radin, R., et al. Sonography of diffuse liver disease. J Ultrasound Med 21:9 (2002), 1023–1032.
58. Jacobs, J.E., Birnbaum, B.A., Shapiro, M.A., et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. AJR Am J Rogentgenol 171:3 (1998), 659–664.
59. Bohte, A.E., van Werven, J.R., Bipat, S., et al. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol 21:1 (2011), 87–97.
60. Ferraioli, G., Tinelli, C., Lissandrin, R., et al. Correlation of the controlled attenuation parameter with indices of liver steatosis in overweight or obese individuals: a pilot study. Eur J Gastroenterol Hepatol 27:3 (2015), 305–312.
61. Fishbein, M., Castro, F., Cheruku, S., et al. Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 39:7 (2005), 619–625.
62. Dioguardi Burgio, M., Bruno, O., Agnello, F., et al. The cheating liver: imaging of focal steatosis and fatty sparing. Expert Rev Gastroenterol Hepatol 10:6 (2016), 671–678.
63. Kalayoglu-Besisik, S., Yeneral, M.N., Caliskan, Y., et al. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in haematopoietic stem cell transplantation patients during the past 10 years. Transplant Proc 37 (2005), 2285–2289.
64. Ortega, J.A., Donaldson, S.S., Ivy, S.P., et al. Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Childrens Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Center. Cancer 79:12 (1997), 2435–2439.
65. DeLeve, L.D., Liver toxicity and haematopoietic stem cell transplantation. Kufe, D.W., Pollock, R.E., Weichselbaum, R.R., et al. (eds.) Holland–Frei Cancer Medicine, 6th edn, 2003, BC Decker, Hamilton (ON).
66. Bearman, S.I., The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 85 (1995), 3005–3020.
67. Rubbia-Brandt, L., Audard, V., Sartoretti, P., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:3 (2004), 460–466.
68. Carreras, E., Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 64:5 (2000), 281–291.
69. Lassau, N., Auperin, A., Leclere, J., et al. Prognostic value of Doppler-ultrasonography in hepatic veno-occlusive disease. Transplantation 74:1 (2002), 60–66.
70. Overman, M.J., Maru, D.M., Charnsangavej, C., et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28:15 (2010), 2549–2555.
71. Han, N.Y., Park, B.J., Sung, D.J., et al. Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy: gadoxetic acid-enhanced and diffusion-weighted MR imaging with clinical–pathologic correlation. Radiology 271:2 (2014), 416–425.
72. Rohatgi, S., Howard, S.A., Tirumani, S.H., et al. Multimodality imaging of tumour thrombus. Can Assoc Radiol J 66:2 (2015), 121–129.
73. Sandrasegaran, K., Tahir, B., Nutakki, K., et al. Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from benign portal vein thrombus in cirrhotic patients. AJR Am J Rogentgenol 201:6 (2013), 1211–1219.
74. Donadon, M., Vauthey, J.-N., Loyer, E.M., et al. Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases. World J Gastroenterol 12:40 (2006), 6556–6558.
75. Hurwitz, H.I., Saltz, L.B., Van Cutsem, E., et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 29 (2010), 1757–1764.
76. Taranti-no, L., Ambrosino, P., Di Minno, M.N.D., Contrast-enhanced ultrasound in differentiating malignant from benign portal vein thrombosis in hepatocellular carcinoma. World J Gastroenterol 21:32 (2015), 9457–9460.
77. Ghabril, M., Vuppalanchi, R., Drug-induced nodular regenerative hyperplasia. Semin Liver Dis 34:2 (2014), 240–245.
78. Brancatelli, G., Federle, M.P., Grazioli, L., et al. Benign regenerative nodules in Budd–Chiari syndrome and other vascular disorders of the liver: radiologic–pathologic and clinical correlation. RadioGraphics 22:4 (2002), 847–862.
79. Brancatelli, G., Federle, M.P., Grazioli, L., et al. Large regenerative nodules in Budd–Chiari syndrome and other vascular disorders of the liver: CT and MR imaging findings with clinicopathologic correlation. AJR Am J Rogentgenol 178:4 (2002), 877–883.
80. Viganò, L., Rubbia-Brandt, L., De Rosa, G., et al. Nodular regenerative hyperplasia in patients undergoing liver resection for colorectal metastases after chemotherapy: risk factors, preoperative assessment and clinical impact. Ann Surg Oncol 22:13 (2015), 4149–4157.
81. Force, J., Saxena, R., Schneider, B.P., et al. Nodular regenerative hyperplasia after treatment with trastuzumab emtansine. J Clin Oncol 34:3 (2016), e9–12.
82. Loomus, G.N., Aneja, P., Bota, R.A., A case of peliosis hepatis in association with tamoxifen therapy. Am J Clin Pathol 80:6 (1983), 881–883.
83. Larrey, D., Freneaux, E., Berson, A., et al. Case report: peliosis hepatis induced by 6-thioguanine administration. Gut 29 (1988), 1265–1269.
84. Chalasani, N.P., Hayashi, P.H., Bonkovsky, H.L., et al. Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic DILI. Am J Gastroenterol 109:7 (2014), 950–966.
85. Brandi, G., De Lorenzo, S., Di Girolamo, S., et al. Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib. Tumouri 101:2 (2015), e46–48.
86. Sato, Y., Fujimoto, D., Shibata, Y., et al. Fulminant hepatitis following crizotinib administration for ALK-positive non-small-cell lung carcinoma. Jpn J Clin Oncol 44:9 (2014), 872–875.
87. van Geel, R.M., Hendrikx, J.J., Vahl, J.E., et al. Crizotinib-induced fatal fulminant liver failure. Lung Cancer 93 (2016), 17–19.
88. Liu, W., Makrauer, F.L., Qamar, A.A., et al. Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol 5 (2007), 917–920.
89. Risson, J.R., Macovei, I., Loock, M., et al. Cirrhotic and malignant ascites: differential CT diagnosis. Diagn Interv Imaging 93:5 (2012), 365–370.
90. Chikarmane, S.A., Tirumani, S.H., Howard, S.A., et al. Metastatic patterns of breast cancer subtypes: what radiologists should know in the era of personalized cancer medicine. Clin Radiol 70:1 (2015), 1–10.
91. Torrisi, J.M., Schwartz, L.H., Gollub, M.J., et al. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 258:1 (2011), 41–56.
92. de Meijer, V.E., Kalish, B.T., Puder, M., et al. Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg 97:9 (2010), 1331–1339.
93. Tamandl, D., Klinger, M., Eipeldauer, S., et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 18:2 (2011), 421–430.
94. Lee, W.M., Larson, A.M., Stravitz, R.T., AASLD Position Paper: the management of acute liver failure: update 2011. Hepatology, 2011, S1–S22.
95. De Wit, M., Boers-Doets, C.B., Saettini, A., et al. Prevention and management of adverse events related to regorafenib. Support Care Cancer 22:3 (2014), 837–846.
96. Yeh, B.M., Liu, P.S., Soto, J.A., et al. MR imaging and CT of the biliary tract. RadioGraphics 29:6 (2009), 1669–1688.
97. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry. July 2009, DILI: Premarketing Clinical Evaluation US Department of Health and Human Services.
98. U. S. Food and Drug Administration/Center for Drug Evaluation and Research. Yervoy (ipilimumab), full prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf. Accessed 17 October 2016.
99. U. S. Food and Drug Administration/Center for Drug Evaluation and Research. Tykerb (lapatinib) full prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf. Accessed 17 October 2016.
100. Dignan, F.L., Wynn, R.F., Hadzic, N., BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol 163:4 (2013), 444–457.